Earnings ·
McKesson Corporation reported preliminary results for the fiscal 2027 first quarter ended June 30, 2026
MCKMcKesson Corp
McKesson Corporation reported preliminary results for the fiscal 2027 first quarter ended June 30, 2026. Consolidated revenues increased 8% to $105.4 billion, driven by growth in North American Pharmaceutical and Oncology & Multispecialty segments. Adjusted earnings per diluted share rose 20% to $9.93, while GAAP earnings per diluted share decreased 18% to $5.15 due to a $293 million redemption value adjustment for redeemable non-controlling interests. The company raised its full-year adjusted EPS guidance to $44.20–$45.00 from the previous range of $43.80–$44.60. McKesson returned $2.6 billion to shareholders, including $2.5 billion in stock repurchases and a 15% dividend increase to $0.94 per share. Additionally, the company announced the name Wellverse for its planned separated Medical-Surgical Solutions business and completed a $1.25 billion minority interest sale of that segment to Apollo Funds. McKesson Corporation operates as a diversified healthcare services leader providing pharmaceutical distribution, biopharma services, and medical-surgical solutions.